Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Johnson & Johnson Pharmaceutical Research & Development, L.L.C. appears in 174 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials174
Recruiting shown0
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled AsthmaNCT01493882 · lead sponsor · 2012-03-01
WITHDRAWN
A Study to Investigate How JNJ-39758979 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis ParticipantsNCT01442545 · lead sponsor · 2011-08-01
COMPLETED
A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes MellitusNCT01381887 · lead sponsor · 2011-06-01
COMPLETED
A Study to Investigate How JNJ-38518168 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis ParticipantsNCT01450982 · lead sponsor · 2011-06-01
COMPLETED
A Study of Two Methods for Determining the Renal Threshold for Glucose in Patients With Type 2 Diabetes MellitusNCT01273558 · lead sponsor · 2011-01-01
COMPLETED
A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes MellitusNCT01230749 · lead sponsor · 2010-12-01
COMPLETED
A Study to Evaluate the Effectiveness of JNJ 40929837 for the Treatment of Asthma Using a Bronchial Allergen Challenge ModelNCT01241422 · lead sponsor · 2010-11-01
COMPLETED
A Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of an Intravenous Solution of JNJ-39588146 or Placebo in Patients With Heart FailureNCT01120210 · lead sponsor · 2010-06-01
COMPLETED
A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes MellitusNCT01128985 · lead sponsor · 2010-03-01
COMPLETED
Becaplermin Use and Cancer Risk in a Patient Population of U.S. Veterans With DiabetesNCT01235260 · lead sponsor · 2010-03-01
COMPLETED
An Efficacy and Safety Study of JNJ-38518168 in Adult Participants With Rheumatoid ArthritisNCT00941707 · lead sponsor · 2010-02-01
TERMINATED
Ketamine Challenge Study With JNJ-40411813NCT01101659 · lead sponsor · 2010-02-01
COMPLETED
A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)NCT01063868 · lead sponsor · 2010-01-01
TERMINATED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and SitagliptinNCT01054118 · lead sponsor · 2009-12-01
COMPLETED
A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful NeuropathyNCT00993018 · lead sponsor · 2009-11-01
TERMINATED
The Effect of Ketamine on AttentivenessNCT01165294 · lead sponsor · 2009-10-01
COMPLETED
A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in ChildrenNCT01050582 · lead sponsor · 2009-10-01
COMPLETED
A Study of the Safety and Effectiveness of JNJ-39758979 in the Treatment of Adults With Persistent AsthmaNCT00946569 · lead sponsor · 2009-08-01
COMPLETED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of JNJ-38431055 in Volunteers With Type 2 Diabetes MellitusNCT00946972 · lead sponsor · 2009-07-01
TERMINATED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Explores What the Body Does to the Drug), and Pharmacodynamics (Explores What a Drug Does to the Body) of JNJ-38431055 in Volunteers With Type 2 Diabetes MellitusNCT00871507 · lead sponsor · 2009-04-01
COMPLETED
A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective DisorderNCT01094249 · lead sponsor · 2009-02-01
COMPLETED
A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy MenNCT01060228 · lead sponsor · 2009-01-01
COMPLETED
Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With SchizophreniaNCT00821600 · lead sponsor · 2008-12-01
COMPLETED
An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With SchizophreniaNCT00728195 · lead sponsor · 2008-11-01
COMPLETED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-38431055 in Healthy Male VolunteersNCT00910923 · lead sponsor · 2008-11-01
COMPLETED
A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the ElectrocardiogramNCT00786838 · lead sponsor · 2008-10-01
COMPLETED
A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable SchizophreniaNCT01812642 · lead sponsor · 2008-07-01
COMPLETED
A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes MellitusNCT01177163 · lead sponsor · 2008-05-01
COMPLETED
A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have DiabetesNCT00650806 · lead sponsor · 2008-05-01
COMPLETED
An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 DiabetesNCT00642278 · lead sponsor · 2008-04-01
COMPLETED
A Study of the Safety of R256918 in Obese PatientsNCT01041677 · lead sponsor · 2008-02-01
COMPLETED
A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 DiabetesNCT00672386 · lead sponsor · 2007-12-01
COMPLETED
A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe DepressionNCT00566202 · lead sponsor · 2007-12-01
COMPLETED
A Study of the Safety and Effectiveness of JNJ-16269110 (R256918) in Overweight and Obese PatientsNCT00622765 · lead sponsor · 2007-11-01
COMPLETED
Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to PaliperidoneNCT00535132 · lead sponsor · 2007-10-01
COMPLETED
An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With SchizophreniaNCT00524043 · lead sponsor · 2007-09-01
COMPLETED
A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With SchizophreniaNCT01150448 · lead sponsor · 2007-09-01
COMPLETED
A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent PatientsNCT00518323 · lead sponsor · 2007-08-01
COMPLETED
Effectiveness and Safety Study for JNJ-18054478 in Asthma Patients.NCT00530166 · lead sponsor · 2007-07-01
TERMINATED
Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese VolunteersNCT01756404 · lead sponsor · 2007-06-14
COMPLETED
An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast CancerNCT00580112 · lead sponsor · 2007-06-01
COMPLETED
A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes MellitusNCT00963768 · lead sponsor · 2007-06-01
COMPLETED
A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral NeuropathyNCT00455520 · lead sponsor · 2007-04-01
COMPLETED
A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and VacavilleNCT00790777 · lead sponsor · 2007-03-01
COMPLETED
Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With SchizophreniaNCT00589914 · lead sponsor · 2007-03-01
COMPLETED
Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With SchizophreniaNCT00590577 · lead sponsor · 2007-03-01
COMPLETED
A Pharmacokinetic Study of the Relative Bioavailability of Paliperidone ER Formulations With Different Release Profiles and a Comparison to Paliperidone IRNCT00791193 · lead sponsor · 2007-03-01
COMPLETED
Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate TherapyNCT00425321 · lead sponsor · 2006-12-01
COMPLETED
Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.NCT00412373 · lead sponsor · 2006-12-01
COMPLETED
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.NCT00397033 · lead sponsor · 2006-11-01
COMPLETED
A Study of the Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release (ER) in Patients With Schizophrenia or Bipolar I DisorderNCT00892125 · lead sponsor · 2006-09-01
COMPLETED
A Study of the Dose Proportionality of Extended Release PaliperidoneNCT00791167 · lead sponsor · 2006-06-01
COMPLETED
A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I DisorderNCT00309686 · lead sponsor · 2006-04-01
COMPLETED
A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I DisorderNCT00309699 · lead sponsor · 2006-04-01
COMPLETED
Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With SchizophreniaNCT00334126 · lead sponsor · 2006-04-01
COMPLETED
A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ERNCT00791713 · lead sponsor · 2006-03-01
COMPLETED
A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I DisorderNCT00299715 · lead sponsor · 2006-02-01
COMPLETED
Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With SchizophreniaNCT00299702 · lead sponsor · 2006-02-01
COMPLETED
Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients.NCT00828958 · lead sponsor · 2006-02-01
COMPLETED
A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or QuetiapineNCT00791622 · lead sponsor · 2006-01-01
COMPLETED

Drugs studied in this sponsor's trials

35 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Johnson & Johnson Pharmaceutical Research & Development, L.L.C. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

docetaxel RxCUI 72962 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial Doxil RxCUI 80773 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial escitalopram RxCUI 321988 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial glimepiride RxCUI 25789 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial ketamine hydrochloride RxCUI 203184 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial montelukast RxCUI 88249 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial olanzapine RxCUI 61381 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial paliperidone RxCUI 679314 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial pioglitazone 30 MG RxCUI 331478 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial quetiapine RxCUI 51272 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial Velcade RxCUI 356733 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor162
collaborator12
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.